Research programme: Antisense oligonucleotides therapeutics - Rescindo Therapeutics
Alternative Names: Research programme: Neurological disorders ASO therapeuticsLatest Information Update: 12 Apr 2022
At a glance
- Originator Rescindo Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodevelopmental disorders
Most Recent Events
- 05 Apr 2022 Early research in Neurodevelopmental Disorders in USA (Parenteral) (Rescindo Therapeutics pipeline, March 2022)